✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Squalamine is an investigational drug.
There have been 12 clinical trials for Squalamine. The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2005.
The most common disease conditions in clinical trials are Macular Degeneration, Macular Edema, and Choroidal Neovascularization. The leading clinical trial sponsors are Ohr Pharmaceutical Inc., Genaera Corporation, and National Cancer Institute (NCI).
Recent Clinical Trials for Squalamine
|Efficacy and Safety Study of Squalamine Ophthalmic Solution in Subjects With Neovascular AMD||Ohr Pharmaceutical Inc.||Phase 3|
|Effect of Squalamine Lactate Ophthalmic Solution, 0.2% in Subjects With Neovascular Age-Related Macular Degeneration||Ohr Pharmaceutical Inc.||Phase 2|
|Squalamine Lactate Eye Drops in Combination With Ranibizumab in Patients With Diabetic Macular Edema (DME)||Ohr Pharmaceutical Inc.||Phase 2|